Nanolek And GC Biopharma Launch New Chickenpox Vaccine To Boost Global Immunity

Nanolek, a leading biopharma company, has applied to the Russian Ministry of Health for approval to begin clinical trials of a new chickenpox vaccine. This innovative vaccine was co-developed with South Korea’s GC Biopharma. If trials are successful, the vaccine could be registered by late 2026 or early 2027. 

The trials will involve eight research centres, including top institutions like Sechenov University’s N.F. Filatov Children’s Health Institute and the N.I. Pirogov Paediatrics Research Institute. Chickenpox is a widespread infection that can lead to serious complications, particularly in infants and adults. As part of Russia’s Immunisation Development Strategy, chickenpox vaccines are planned to be added to the National Immunisation Schedule by 2027.